X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Cipla: AGM Notes - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Sep 5, 2002

    Cipla: AGM Notes

    Cipla declared a 30% growth in revenues for the first five months ended August’01 at its AGM held on 4th September'02. Considering 1QFY03 figures, where revenues grew by 35%, the first five months numbers reflect continued better performance in two months viz July & August’02. However, the management gave a conservative revenue guidance of only 20% growth for the year.

    Exports contribution to shoot
    Backed by strong growth in exports, Cipla’s management expects export contribution to rise to 40% in the current year as against 35% for FY02. The new manufacturing facility at Goa has now become operational and the facility is expected to be dedicated for exports. The manufacturing facility has recently secured the WHO (World Health Organisation) and the UK drugs regulator approval to export CFC free asthma inhalers to the international markets.

    Anti-asthma exports to Europe to finally begin
    The company is set to launch the world’s only budesonide (an asthma drug) formulation in CFC-free, metered-dose inhalers in Germany and throughout Europe. The approval for sale in Germany is expected soon and exports are expected to start by end of the current year. Investors were eyeing this opportunity for a long time, as the market for this product in the west is huge. With CFC (Chlorofluorocarbons) inhalers to be compulsorily phased out by 2010, the eco-friendly non-CFC based inhalers are expected to see a quantum jump in demand going forward. The European market, which is the biggest market for inhaler drugs, is estimated to be around US$ 3.8 bn currently.

    Generic strategy
    The generic strategy of the company is to enter bulk drug supply arrangements with companies well entranced in the generic markets. These arrangements are typically to supply hard to manufacture specialty bulk drugs. The management also clarified that the company has started selling bulk Omeprazole to the US partner, Andrx (though Andrx selling the drug is still contingent on the ongoing litigation). The company informed that Cipla was looking to market 50-60 products in Europe in the next few years. It has 10 registrations in the US and a further 21 registrations are under discussion. It hopes to file 20-25 APIs (active pharmaceutical ingredient) in the coming year.

    New product launches
    In the domestic market, Cipla will also be marketing 50-60 new drug formulations in 2002-03 to keep its product portfolio broad-based. The company will shortly launch a new Once a day AIDS dose kit. Currently, the company commands 75% market share for AIDS medication in the Indian market.

    Foray in Biotech
    The company informed that it is interested in venturing into biotech and Genetic engineering with a suitable foreign partner. Cipla is evaluating options for such possible tie-ups.

    No immediate plans for buyback
    The shareholders have given an in principal approval for allowing buyback of shares at a later stage. However, the management has denied any immediate intention of a buyback of its shares in the current year.

    We maintain our estimates of 23% growth in topline and around 19% growth in bottom line for FY03. At the current market price of Rs 963, the stock trades at around 19x, FY03 E earnings.

     

     

    Equitymaster requests your view! Post a comment on "Cipla: AGM Notes". Click here!

      
     

    More Views on News

    Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

    Mar 8, 2017

    Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

    Sep 19, 2016

    Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

    Aug 21, 2017

    Most Indians who cannot find jobs, look at becoming self-employed.

    It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

    Aug 16, 2017

    The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

    Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

    Aug 22, 2017

    Post demonetisation, a cut in bank savings deposits rates was in the offing.

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    CIPLA SHARE PRICE


    Aug 24, 2017 02:43 PM

    TRACK CIPLA

    CIPLA 5-YR ANALYSIS

    Detailed Financial Information With Charts

    COMPARE CIPLA WITH

    MARKET STATS